Asim Shahmalak
He is a frequent media spokesman, and has written about the importance placed in hair over the centuries and the fact that baldness until recently was not recognised as a social or medical issue, despite the sometimes catastrophic impact it can have on confidence and mental well-being. He wrote: "Male pattern baldness (MPB), the main cause of hair loss, affects an estimated quarter of men by the age of 30 and two thirds by the age of 60. Until recently, the impact baldness might have on confidence and well-being was little understood or recognised by the medical profession at large."
Setipiprant
However, following the discovery in 2012 that the prostaglandin D receptor (DP/PGD) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly. , setipiprant is currently under development by Allergan for the prevention of androgenic alopecia after their successful acquisition of Kythera.